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ABSTRACT
A ribonuclease, RNase T-tat, specifically designed to
hydrolyze the TAR RNA of HIV-1 virus has been
engineered. The protein was made by domain
swapping the TAT peptide at the loop 3 position of
ribonuclease T1. The RNase T-tat maintains a
guanine-specific RNA hydrolytic activity, and char-
acteristically displayed a specific affinity for the TAR
RNA of HIV-1. In the in vitro and in vivo assays, the
RNase T-tat preferentially inhibited the expression
of TAR-bearing mRNA through cis-TAR targeting,
suggesting that RNase T-tat may be potentially
useful for the disruption of the initial stage of the
transcription process of HIV-1 virus.
INTRODUCTION
Recently, protein engineering has aimed at designing and
producing novel proteins with desirable functions and this
has emerged into a new stage due to signiﬁcant develop-
ments in three-dimensional structure analysis combined
with advanced knowledge of important cellular events.
The design of the protein’s properties that surpass the
performance of native proteins by protein engineering has
the potential to create protein drug and this has become a
trend in pharmaceutical industry. The pre-requisite of this
is to know where and how the engineering acts on the
protein. For RNA virus related diseases, the utilization of
an RNase- or ribozyme-based strategy aims for the
destruction of the viral RNA (1,2). In the case of HIV-1
virus, the transcription of viral RNA is heavily dependent
upon the formation of an RNP complex that results from
the interaction between an early TAR (activation-respon-
sive region) RNA transcript and the viral TAT (trans-
activator of transcription) protein (3–6). A consequence of
the formation of the RNP complex is the prompt
recruitment of host cell transcription factors allowing
eﬃcient viral transcription (5,6). Thus, one way to
interfere with the proliferation of HIV-1 virus in infected
cells would lie in the destruction of the early TAR RNA
scaﬀold. Based on this notion, the ribonuclease activity of
ribonuclease T1 (RNase T1) was the choice for this
purpose. This was made possible because the structure of
RNase T1 is well understood and has proven to be a useful
model for the study of protein folding and stability (7–10).
More importantly, a recent study has indicated that the
peripheral loop L3 of RNase T1 can be swapped with a
speciﬁc RNA-binding motif without changing the base-
speciﬁcity of RNase T1 but the change results in the gain
of a double-stranded speciﬁcity (11). It was therefore our
intention to use domain swapping to make a new RNase,
denoted as RNase T-tat, which acts against TAR
transcription of HIV-1 virus. RNase T-tat consists of the
Tat peptide sequence of RKKRRQRRR from the TAT
protein at the L3 position of the RNase T1. Based on the
speciﬁc cis-acting recognition of TAR RNA by the Tat
peptide (3–6,12,13), theoretically, the ribonuclease activity
of RNase Tat is expected to inactivate the transcription of
HIV-1 virus on gaining cell entry (5,6). With this
expectation, RNase T-tat may be able to play a role to
restraining the transcription of HIV-1 virus.
MATERIALS AND METHODS
Construction ofthe RNase T-tat gene
The gene coding for RNase T-tat was cloned by the
polymerase chain reaction (PCR) using pGEM(T)/RNase
T1 as the template by two primers, a C-primer
(50-NNNNNGGATCCCCAGGTGCGGACCGTGTGG
TGTTC-30) and a N primer (50-NNNNNGGATCCTCT
TCTTCTTTGTCTTCTTTTTTTTCTTCCAGAGCTCG
AATCGGCCACTCATA-30). The BamHI restriction sites
are underlined. The N primer carried an insert site coding
the Tat-peptide (27 bases in capital alphabet) plus 26 bases
(in italics) that encode for the 30 end of b2 strand of RNase
T1. The PCR fragment ( 3.5kb) was digested by restric-
tion enzyme DpnI to eliminate the endogenous pGEM(T)/
RNaseT1 plasmid and further digested with restriction
enzyme BamHI to allow ligation to create the pGEM/T-tat
plasmid.The cytosolic expressionvector pET28a/T-tat was
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sequence of the RNase T-tat gene was veriﬁed by DNA
sequencing. The pET28a/T-tat plasmid was propagated in
Escherichia coli strain JM109, and protein was puriﬁed
through Ni-chromatography. Similarly, the RNase T-tat
gene was also cloned into a eukaryotic CMV-driven
plasmid using the same strategy.
The procedure for the construction of pET28a/
T-tatH95S was essentially the same as described earlier,
except that pGEM(T)/RNase T1H92S was used as the
template for PCR ampliﬁcation. The mutant protein was
puriﬁed by Ni-chromatography. A eukaryotic expression
vector, pCMV/TAR-EGFP was also constructed using the
same strategy. The vector carries a TAR RNA sequence
(57-mer) joined to the NH2-terminal of the coding
sequence of EGFP driven by a CMV promoter.
Molecular modeling
The tertiary structure of RNase T-tat was simulated on
the basis of the crystal structure of RNase T1 (Broo-
khaven PDB entry iRNT). Using energy minimization and
diﬀerent conditions of constraints, a RNase T-tat struc-
ture was generated. All calculations were performed on an
SGE Origin 2000 computer using the program DESCOV-
EER as implemented in the package Insight II (Molecular
Simulation, San Diego, CA).
RNA-impregnated polyacrylamide gelelectrophoresis
Puriﬁed recombinant RNase T-tat was analyzed electro-
phoretically in agel contained 2.5mg/ml of large fragments
of ribosomal RNA. The presence of RNA fragments in
the gel did not interfere with protein separation. After
electrophoresis, the gel was rematured by incubation in
buﬀer containing 10mM Tri–HCl, pH 7.4 and 25%
2-propanol (to extract SDS), and this was followed by
four washes with incubation buﬀer without 2-propanol.
ThegelwasthenstainedwithtoluidineblueO(2%solution
inH2O).Anegativestaining eﬀect(whiteincolor)againsta
blue background (the stained RNA) represented the
ribonucleolytic activity of protein present on the gel.
The determination of the base speciﬁcity was carried out
using the same principle except that that the gel contained
mono-ribonucleotide polymer (poly U, Poly A and Poly
G, or poly C) instead of RNA fragments.
RNA gel-mobility shift and Millipore assay
A 57-mer oligo RNA that mimics the structure of the TAR
RNA was synthesized using phage T7 RNA polymerase
(Promega Co. USA) and synthetic DNA oligomers as
templates. The oligomers used had the sequence carried a
complementary T7 promoter and the nucleotide sequence
of TAR RNA. They were annealed at 908C for 3min
followed by cooling on ice. The transcription reaction was
carried out at 378C for 1h under conditions as described
previously (11). At the end of transcription, the transcript
was heated to 908C for 2min in buﬀer and renatured
by gradual overnight cooling to 48C, which allowed
the formation of a secondary structure that imitated
the structure of TAR RNA. The 57-mer TAR RNA was
30 end-labeled with cytidine 30,50-[a-
32P]bisphosphate as
previously described (11).
The gel mobility shift assay was carried out in a 10ml
reaction mixture containing 53rM radioactive [
32P]-57
mer TAR with various amounts of RNase T-tat or RNase
T-tat H95S mutant protein in binding buﬀer (20mM
Tris–HCl, pH 8.0; 100mM KCl; and 10mM DTT, 1mM
EDTA and 10% glycerol) at 48Co r2 5 8C, for 15min and
analyzing using an 8% native polyacrylamide gel. The
presence of radioactive RNA and RNP was detected using
a phosphoimager.
The Millipore assay was carried out as follow: [
32P]-
TAR RNA or [
32P]-5S rRNA was incubated with
increasing amounts of RNase T-tat H95S protein in
binding buﬀer for 15min at 258C. The reaction mixture
was ﬁltered through a nitrocellulose membrane (Millipore,
type HA, 0.45mm) that had been soaked in binding buﬀer;
ﬁltration was with a vacuum of 55Torr. The radioactivity
retained on nitrocellulose membrane was determined.
Cell entry assay
The ability of the RNase T-tat molecule to enter the cell
was veriﬁed by both a protease-elimination assay and by
direct microscopic ﬂuorescent examination. The protease-
elimination assay was carried by incubating embryonic
kidney 293T cells with [
35S]-RNase T-tat (0.5mg, prepared
by in vivo labeling) with or without chloroquine in PBS for
30min at 258C. At 6h and 24h post-incubation, the same
numbers of treated and non-treated cells were taken and
incubated with trypsin (5mg/ml, 30min at 258C). After
thoroughly washing cells with PBS, the trypsinized cells
were then lysed with denaturation solution containing 1%
SDS and analyzed on a SDS-containing polyacrylamide
gel. The presence of a radioactive protein band was
visualized by a phosphoimager.
The direct microscopic ﬂuorescent examination was
carried out as follows. Texas red-conjugated RNase T-tat
(TR-RNase T-tat), RNase T1 (TR-RNase T1) and bovine
serum albumin (TR-BSA) were prepared as previously
described (14). These ﬂuorescent proteins in PBS were
separately applied to 293T cells that had been seeded on
a1 5 15mm coverslip, for 30min at 258C. After removal
of the excess ﬂuorescent protein by extensively washing,
growth was continued in fresh medium. At 6h post-
incubation, the cells were examined under a confocal
ﬂuorescence microscope and also by phase contrast
microscopy.
The in vitro activity ofRNase T-tat
The preferential inhibitory eﬀect of RNase T-tat on in vitro
translation of TAR-EGFP mRNA was carried out
using two mRNAs (luciferase and TAR-EGFP mRNA;
5mg each) in rabbit reticulocyte lysate containing
[
35S]methionine in the presence (0.2mg) or the absence of
RNase T-tat. The reaction was carried out for 60min at
258C and analyzed by SDS-containing polyacrylamide gel.
The translated products were visualized using a phophoim-
ager. Luciferase mRNA was purchased commercially. The
TAR-EGFP mRNA was synthesized by the RiboMax
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vector (pCMV/TAR-EGFP) as the template.
Detection ofthe invivo activity ofRNase T-tat by
ananoparticulate single cell activity assay
A hepatoma cell line containing a stable gene coding
for either TAR-EGFP or EGFP (kindly provided by
Dr J. S. Su, Genome Center, National Yang-Ming
University, Taiwan) was used to directly observe the
in vivo activity of RNase T-tat. This was carried out by our
currently developed nanoparticulate single cell activity
assay (patent pending). In brief, nano-magnetic beads
(NMB) (TANBead, USPIO-101; purchased from Taiwan
Nanotech Inc. Taoyuan, Taiwan) were coated with
polylysine (PLL, MW 4000; Sigma-Aldrich Co, USA)
using EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodii-
mide hydrochloride) conjugation. The polylysine-coated
NMBs were magnetically separated from un-reacted
EDC, and were subjected to labeling with Alexa ﬂuor
555 (Molecular Probe, Eugene, USA) according to
manufacture’s suggested procedure. The ﬂuorescent poly-
lysine-coated NMB were coupled with an excess amount
of plasmid pCMV/RNase T-tat under constant stirring.
Uncoupled DNA plasmid was again removed by magnetic
procedure. The NMB/plasmid complex was delivered into
the hypatoma cells (with an excess number of NMB
complexes to enhance cell entry) using electroporation.
The electroporation took place in serum free DNEM
medium in less than one second. Immediately after
electroporation, the free NMB complexes were separated
from cells by the magnetic removal procedure. Treated
cells were then seeded on a coverslip for further growth.
Under diﬀerent ﬂuorescent excitations, the transfected
cells gave constant green ﬂuorescence because of the
expression of EGFP or TAR-EGFP, and the NMB
showed up as a red spot. Thus, cells impregnated with a
red ﬂuorescent NMB indicated these cells had been
successfully transfected with plasmid DNA containing
the RNase T-tat gene. The ﬂuorescent intensities in cells
with and without internalized NMB were quantitatively
measured. The measurement was carried out both for




In this study, we have constructed a gene coding for the
RNase T-tat by genetic manipulation. The RNase T-tat
consists of the Tat peptide sequence of RKKRRQRRR,
which was inserted at loop position of RNase T1. The
gene was expressed in E.coli cells and the recombinant
RNase T-tat was subsequently puriﬁed (Figure 1a). The
recombinant protein RNase T-tat displays the same
guanyl base-speciﬁcity as RNase T1 (7,8), which was
detected by RNA-impregnated polyacrylamide gel assay
(Figure 1a). This indicates that insertion of Tat peptide
does not jeopardize the original ribonuclease activity
and these results are similar to the reported case for
RNase Ta (11).
As an initial step, we have inspected the structure of the
engineered RNase T-tat and its recognition of the TAR
RNA by molecular modeling. The simulated structure of
RNase T-tat has the basic b-pleated sheet conformation
with a folded Tat peptide free on the surface of the protein
molecule. The b-pleated sheet can be superimposed on the
structure of RNase T1 (Figure 1b). In molecular docking,
the Tat domain ﬁtted the major groove of the TAR RNA
with closed contact to the UCU bulge (Figure 1c), which is
very like that found in previous studies of Tat-TAR
Figure 1. Characterization of RNase T-tat. (a) The expression, puriﬁcation and ribonuclease activity of RNase T-tat. Lanes 1–3 are Coomassie
staining of a 15% SDS-polyacrylamide gel analyzing the expression of RNase T-tat gene with (lane 1) and without (lane 2) IPTG induction and the
puriﬁed recombinant protein RNase T-tat (lane 3). Lanes 4 and 5 are the RNA-impregnated gel electrophoresis analysis of the ribonuclease activity
of recombinant RNase T-tat against naked RNA (lane 4) and poly G (lane 5). The gels were visualized using toluidine blue O staining of RNA.
Negative results were obtained for poly A- and poly U-impregnated gels. (b) The simulated structure of RNase T-tat (yellow ribbon with the TAT
peptide in red) superimposed on the structure of RNase T1 (green ribbon whose L3 loop is blue in color). (c) Molecular docking of RNase T-tat with
TAR RNA. Both protein (gray) and RNA (orange) present in backbone mode except for the contact region, which is highlighted with a wire-
structure in red color for the amino acid residues and yellow color for the UCU bulge. (d) Atomic detail of interaction between the Arg70 of the
RNase T-tat and U33 of TAR RNA. The distances indicated (underlined) aﬀect docking and the measurements were made after docking.
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are measured (Figure 1d), they are close to the reported
geometric values observed previously (13). This informa-
tion supports the feasibility of the proposed RNase T-tat
as a molecule that can recognize TAR RNA.
Specific binding ofRNase T-tat toTAR RNA
Experimentally, we tested the recognition TAR RNA by
RNase T-tat using a gel-mobility shift assay using a
synthetic 57-mer oligo TAR RNA (Figure 2a) as
substrate. The results showed that RNase T-tat has
ribonucleolytic activity and therefore was not surprising
to ﬁnd that the TAR RNA was cleaved by RNase T-tat at
258C (Figure 2b). The cleavage occurred at both single
stranded (G31, G32 and G33), and double stranded (G35,
G43, G51, G52 and G53) guanine bases, which is diﬀerent
from the original RNase T1 single stranded-speciﬁcity (7)
(Figure 2b).
In order to avoid ribonuclease activity at normal
temperature, the recognition between RNase T-tat and
the TAR RNA was determined at 48C. The result of the
gel-mobility shift assay showed an up-shifted RNP
complex (Figure 2c). The formation of this RNP is
speciﬁc because in a parallel experiment, RNase T1 was
unable to form such an up-shifted complex at 48C
(Figure 2c). In the eﬀort to determine the aﬃnity between
RNase T-tat and TAR RNA, we created a defective
mutant, RNase T-tatH95S (His95 mutated to serine), and
used this in the kinetic binding assay. The corresponding
mutation at this His residue in RNase T1 (His92) is known
to reduce RNA hydrolysis by RNase T1 to a minimum
but to maintain the protein’s structural integrity (8,15,16).
Accordingly, the gel-mobility shift assay was carried out
again with RNase T-tatH95S at 258C. The results showed
that the RNase T-tatH95S up-shifted the TAR RNA, but
produced no sign of RNA digestion (Figure 2d).
Separately, a Millipore ﬁltration assay was adapted to
determine a saturation-binding curve (Figure 2e), and the
apparent association constant for the interaction of
RNase T-tatH95S with TAR RNA was determined by
constructing a double reciprocal plot of the data. This
yielded a Ka
0 value of 1.8 10
7M
 1. The aﬃnity suggests
that RNase T-tat may prefer to recognize TAR RNA
rather than any other RNA molecule.
Figure 2. Recognition between RNase T-tat and a 57-mer TAR RNA. (a) The structure of 57-mer oligo TAR RNA. Arrows are the cleavage sites
caused by RNase T-tat. (b) The hydrolysis of TAR RNA by RNase T-tat. The reaction mixture contained 30end labeled 57-mer TAR RNA and
various amounts of RNase T-tat. The analysis was on a 15% sequence polyacrylamide gel containing 8M urea. Partial alkaline hydrolysis (Alk.
Hyd.) was carried out according to a standard protocol. (c) Binding of RNase T-tat to the 57-mer TAR RNA at 48C. The assay was analyzed using
8% native polyacrylamide gel. Lane T1 contains was 2mg of RNase T1. (d) Binding of RNase T-tat mutant H95S to the 57-mer TAR RNA at 258C.
The radioactive RNA and RNP in (b), (c) and (d) were detected using a phosphoimager. (e) Millipore binding assay. Both binding of mutant RNase
T-tat H95S to [
32P]-TAR RNA and human [
32P]-5S rRNA were carried out in parallel.
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mRNA translation assay containing two mRNAs, a
luciferase mRNA and a TAR-carrying EGFP mRNA in
the rabbit reticulocyte translation system with or without
RNase T-tat. The TAR-carrying EGFP has a 57-mer
TAR RNA sequence joined to the NH2-terminal end of
the coding sequence of EGFP (Figure 3a). The results of
the in vitro translation showed that both proteins were
equally expressed in the absence of RNase T-tat
(Figure 3b). However, in the presence of RNase T-tat,
the production of luciferase protein was slightly reduced,
but that of EGFP had totally been eliminated (Figure 3b).
Under the same conditions, the non-TAR-carrying
mRNA (luciferase) was aﬀected to a very much lesser
extent (Figure 3b).
Cell entry ofRNase T-tat
The Tat protein or a Tat-peptide conjugated protein has
an ability to enter cells (17–22) or living mice (23) and this
is well documented. Based on this, we have examined
whether or not the Tat peptide within the structure of
RNase T-tat was able to direct RNase T-tat into cells.
This was carried out using a protease-elimination assay
with radioactive [
35S]-RNase T-tat and ﬂuorescent micro-
scopic examination. The results of elimination assay
clearly showed that RNase T-tat was able to enter 293T
cells (Figure 4a). Similarly, using ﬂuorescent microscopy,
ﬂuorescent Texas red-conjugated RNase T-tat (TR-
RNase T-tat) was located inside of the treated 293T
cells after a short external exposure (Figure 4b), whereas
Texas-red conjugated RNase T1 (TR-RNase T1) and
Texas-red conjugated-BSA (TR-BSA) showed no sign of
any entry (Figure 4b). It is of worth noting that the
eﬃciency of cell entry as measured by the internalized
ﬂuorescent RNase T-tat was unexpectedly low with
a yield of  20% compared with values in reported studies
where the Tat peptide itself was used to mediate cell
entry (24,25).
The invivo activity ofRNase T-tat
There remains a question of whether the described
preferential targeting of TAR-carrying mRNA is able to
cause in vivo inhibition under physiological conditions
inside the cell. To test such physiological relevance, we
have treated hepatoma cells that had carried a stable
TAR-EGFP gene with diﬀerent dosage of RNase T-tat,
and measured the inﬂuence of RNase T-tat on the
expression of EGFP. Using this approach (data not
shown), it was diﬃcult to see any diﬀerence caused by the
action of RNase T-tat on the TAR-EGFP cells compared
with EGFP cells. A similar non-signiﬁcant outcome was
also observed when the expression of EGFP mRNA was
measured by northern blotting of both treated cells. Such
observations could be attributed to the low percentage cell
entry of RNase T-tat as described earlier. Interestingly, it
was observed that the level of GAPDH mRNA in both
treated cells was unaﬀected regardless of the presence or
absence of RNase T-tat.
In an eﬀort to demonstration that RNase T-tat has a
speciﬁc in vivo activity on TAR-associated RNA,
we carried out a single cell activity assay. The principle
of this assay is the use of a ﬂuorescent NMB as a gene-
carrier and an indicator. Brieﬂy, the NMB carried plasmid
containing the CMV-driven RNase T-tat gene and this
was mechanically delivered into the cells. The activity of
RNase T-tat was followed in an individual cell impreg-
nated with the ﬂuorescent NMB (Figure 5a). The precise
Figure 4. Cell entry of RNase T-tat. (a) The protease elimination
assay. Lane 1, [
35S]-RNase T-tat alone; lane 2, trypsinization of
[
35S]-RNase T-tat; lanes 3 and 4, cell lysate 6h post-treatment with or
without chloroquine, respectively; lanes 5 and 6, cell lysate of 24h post-
treatment with or without cholorquine, respectively. The radioactive
protein was detected by a phosphoimager using a SDS-polyacrylamide
gel electrophoresis. (b) The cellular localization of the ﬂuorescent
RNase T-tat. Texas red-conjugated RNase T-tat (TR-RNase T-tat) and
RNase T1 (TR-RNase T1) were separately applied to 293T cells as
described in text. The presenting pictures were combining images that
observed under a confocal ﬂuorescence microscopy and phase contrast
microscopy.
Figure 3. The in vitro activity of RNase T-tat on the expression of
TAR-carrying mRNA. (a) The schematic presentation of the structure
of TAR-carrying EGFP (TAR-EGFP) that was used for the in vitro
inhibitory translation assay. (b) The in vitro inhibitory translation
assay. The translation of TAR-carrying EGFP mRNA and luciferase
mRNA was carried out in the rabbit reticulocyte system for 45min
with or without RNase T-tat and analyzed using 15% SDS-
polyacrylamide gel electrophoresis and a phosphoimager.
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was registered by measuring the GFP ﬂuorescence
intensity in single NMB-impregnated cells. This showed
that the ﬂuorescent intensity was gradually diminished in
NMB-impregnated cell containing the stable TAR-EGFP
gene with time after NMB delivery increased (Figures 5a
and b). In parallel, little or no change in ﬂuorescent
intensity was found for NMB-impregnated cells that
contained the stable EGFP gene (Figures 5a and b).
DISCUSSION
Utilizing an RNase- or ribozyme-based strategy against
RNA related diseases has been suggested (1,2). Examples
of fusing a RNA-binding domain to aid recognition and
cleaved of HIV-RNA (26), the use of a ribozyme (27) or
other approaches (25) to target the HIV-1 have been
proposed in order to inactivate the machinery of HIV-1
transcription. Herein, we have successfully created an
engineered ribonuclease, which potentially targets the
initial stage of the transcription process of the HIV-1
virus. The action of RNase T-tat was ﬁrst demonstrated
by showing that RNase T-tat selectively recognized and
hydrolyzed a synthetic 57-mer TAR RNA substrate. It is
interesting that the engineering RNase T-tat not only
displayed single stranded guanine base ribonuclease
activity, but was also capable of cleaving guanine bases
at the helix region around the bulge UCU of 57-mer TAR
RNA. This expansion of the ribonuclease activity to
double stranded cleavage can be attributed to conforma-
tional changes (4,6) in the helix region after the bulge
UCU of the TAR RNA contacts the TAT-peptide of
the RNase T-tat. Nevertheless, this is not a problem
as the broadened speciﬁcity makes certain that RNase
T-tat will eﬀectively hydrolyze the TAR RNA. The
observation that RNase T-tat selectively hydrolyzed the
TAR RNA-associated mRNA in the in vitro duo-mRNA
translation reaction clearly supports the protein’s destruc-
tive ability.
In essence, by design, the protein transduction property
of the Tat peptide (17,18,21) has been incorporated into
Figure 5. The suppression of the expression of TAR-carrying EGFP by RNase T-tat as detected at single cell level. (a) The observations of the
suppression of the expression of EGFP (shown in green) by internalized NMB (red) that carried RNase T-tat gene measured at diﬀerent time
intervals post-NMB delivery. The presenting photos are the merged images derived from results of phase contrast microscopic and ﬂuorescent
microscopic examination. Arrows showed cells that have impregnated with NMB(s). (b) The quantiﬁcation of the eﬀects of RNase T-tat as measured
by the ﬂuorescent intensity. The ﬂuorescent intensity in a cell that contains no NMB was used as a 100% control for EGFP expression. Each bar
represents an average measurement of 10 or more cells.
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positive results derived from both the protease-elimination
assay and the ﬂuorescent examination clearly conﬁrmed
the transductive nature of the Tat peptide in RNase T-tat
as originally envisaged, except that a much lower eﬃciency
of cell transduction was observed. Interestingly, we have
observed that once RNase T-tat has entered a cell, it can
easily reach the nucleus. Thus, despite the low eﬃciency of
cell entry, the results show promise with respect to the
action of RNase T-tat because the trans-activation of
HIV-1 takes place in the nucleus (22), which is vital to
ﬁnal aim of disabling the proliferation of HIV-1.
In this study, the selective targeting of RNase T-tat to
TAR-related RNA was ﬁrst demonstrated by the in vitro
duo-mRNA translation experiment, and this was followed
up with a novel single cell activity assay system, which
showed that internalized RNase T-tat molecules carried
the same physiological relevance inside a cell. These results
provide strong evidence that RNase T-tat is able to
selectively prevent the expression of the TAR-associated
EGFP, implying that RNase T-tat shows preferential
recognition of the TAR-carrying mRNA (TAR-EGFP)
through a cis-acting aﬃnity and consequently hydrolyzes
the RNA. It further suggests that RNase T-tat may be
potentially useful for the disruption of TAR RNA of
HIV-1 virus.
The signiﬁcance of this study is providing a good
example of the development of a RNA-oriented protein
drug that can be used against a RNA virus. In addition,
the technological platform of the single cell activity assay
system demonstrates the ability to analyze gene action at a
single cell level. The system is not only an excellent
approach to the veriﬁcation of gene activity, but also can
be adapted to the screening potential drugs against HIV-1
virus, including chemicals and other types of biological
materials.
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